Calton & Associates Inc. lowered its holdings in iShares Biotechnology ETF (NASDAQ:IBB – Get Rating) by 12.5% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,105 shares of the financial services provider’s stock after selling 585 shares during the period. Calton & Associates Inc.’s holdings in iShares Biotechnology ETF were worth $534,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Consolidated Planning Corp acquired a new position in iShares Biotechnology ETF during the 3rd quarter worth approximately $32,000. Future Financial Wealth Managment LLC acquired a new position in iShares Biotechnology ETF during the 4th quarter worth approximately $30,000. Gradient Investments LLC grew its holdings in iShares Biotechnology ETF by 99.0% during the 4th quarter. Gradient Investments LLC now owns 201 shares of the financial services provider’s stock worth $31,000 after acquiring an additional 100 shares in the last quarter. Steward Financial Group LLC acquired a new position in iShares Biotechnology ETF during the 4th quarter worth approximately $34,000. Finally, Dixon Hughes Goodman Wealth Advisors LLC acquired a new position in iShares Biotechnology ETF during the 4th quarter worth approximately $38,000. Institutional investors own 63.88% of the company’s stock.
Shares of iShares Biotechnology ETF stock opened at $113.25 on Thursday. The company has a fifty day simple moving average of $116.33 and a 200-day simple moving average of $128.58. iShares Biotechnology ETF has a 12-month low of $104.29 and a 12-month high of $177.37.
About iShares Biotechnology ETF (Get Rating)
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
- Get a free copy of the StockNews.com research report on iShares Biotechnology ETF (IBB)
- Victoria’s Secret Stock is Out of the Box
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.